| Revision as of 12:43, 29 July 2024 editJonesey95 (talk | contribs)Autopatrolled, Extended confirmed users, Page movers, Mass message senders, Template editors378,696 edits Fix Linter errors. (wikilink inside external link)← Previous edit | Latest revision as of 09:18, 22 August 2024 edit undoValenzuela400 (talk | contribs)Extended confirmed users14,405 edits better image | ||
| Line 52: | Line 52: | ||
| }} | }} | ||
| '''Levodropropizine''' is a ]. It is the ] of ]. It acts as a peripheral antitussive, with no action in the ].<ref>{{cite journal | vauthors = De Blasio F, Dicpinigaitis PV, Rubin BK, De Danieli G, Lanata L, Zanasi A | title = An observational study on cough in children: epidemiology, impact on quality of sleep and treatment outcome | journal = Cough | volume = 8 | issue = 1 | pages = 1 | date = January 2012 | pmid = 22269875 | pmc = 3274450 | doi = 10.1186/1745-9974-8-1 | doi-access = free }}</ref> It does not cause ] such as ] or ] which can be produced by ] antitussives such as ] and its derivatives. | '''Levodropropizine''' is a ]. It is the ] of ]. It acts as a peripheral antitussive, with no action in the ].<ref>{{cite journal | vauthors = De Blasio F, Dicpinigaitis PV, Rubin BK, De Danieli G, Lanata L, Zanasi A | title = An observational study on cough in children: epidemiology, impact on quality of sleep and treatment outcome | journal = Cough | volume = 8 | issue = 1 | pages = 1 | date = January 2012 | pmid = 22269875 | pmc = 3274450 | doi = 10.1186/1745-9974-8-1 | doi-access = free }}</ref> It does not cause ] such as ] or ] which can be produced by ] antitussives such as ] and its derivatives. | ||
| ] | ] | ||
| In September 2021, Korea United Pharm file lawsuits against 15 drug manufacturers as ] protection for its 2017 registered ] drug Levotics CR Tab. (levodropropizine). The cases are anchored on violation of its patent for "Method for Preparing Sustained-Release Tablets Containing Levodropropizine."<ref>{{cite news |last1=Chan-hyuk |first1=Kim |title=Korea United Pharm sues 15 drugmakers to protect cough suppressant's patent|url= https://www.koreabiomed.com/news/articleView.html?idxno=12239|accessdate=July 29, 2024 |publisher=] |date=September 9, 2021}}</ref> In September 2023, KUP signed a five-year $52.1 million contract with MCQ, a Thai-based pharmaceutical company, for supply of its ] drug, Levotics CR Tab (levodropropizine).<ref>{{cite news |last1= |first1= |title=Korea United Pharm to supply mucoactive drugs worth $52 million to Thailand|url=https://www.koreabiomed.com/news/articleView.html?idxno=22024 |accessdate=July 29, 2024 |publisher= ]|date=September 9, 2023}}</ref> | In September 2021, Korea United Pharm file lawsuits against 15 drug manufacturers as ] protection for its 2017 registered ] drug Levotics CR Tab. (levodropropizine). The cases are anchored on violation of its patent for "Method for Preparing Sustained-Release Tablets Containing Levodropropizine."<ref>{{cite news |last1=Chan-hyuk |first1=Kim |title=Korea United Pharm sues 15 drugmakers to protect cough suppressant's patent|url= https://www.koreabiomed.com/news/articleView.html?idxno=12239|accessdate=July 29, 2024 |publisher=] |date=September 9, 2021}}</ref> In September 2023, KUP signed a five-year $52.1 million contract with MCQ, a Thai-based pharmaceutical company, for supply of its ] drug, Levotics CR Tab (levodropropizine).<ref>{{cite news |last1= |first1= |title=Korea United Pharm to supply mucoactive drugs worth $52 million to Thailand|url=https://www.koreabiomed.com/news/articleView.html?idxno=22024 |accessdate=July 29, 2024 |publisher= ]|date=September 9, 2023}}</ref> | ||
Latest revision as of 09:18, 22 August 2024
Chemical compound Pharmaceutical compound | |
| Clinical data | |
|---|---|
| AHFS/Drugs.com | International Drug Names |
| ATC code | |
| Pharmacokinetic data | |
| Protein binding | 11-14% |
| Excretion | 83% via urine within 96 h |
| Identifiers | |
IUPAC name
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.167.719  |
| Chemical and physical data | |
| Formula | C13H20N2O2 |
| Molar mass | 236.315 g·mol |
| 3D model (JSmol) | |
SMILES
| |
InChI
| |
| (what is this?) (verify) | |
Levodropropizine is a cough suppressant. It is the levo isomer of dropropizine. It acts as a peripheral antitussive, with no action in the central nervous system. It does not cause side effects such as constipation or respiratory depression which can be produced by opioid antitussives such as codeine and its derivatives.
In September 2021, Korea United Pharm file lawsuits against 15 drug manufacturers as patent infringement protection for its 2017 registered antitussive drug Levotics CR Tab. (levodropropizine). The cases are anchored on violation of its patent for "Method for Preparing Sustained-Release Tablets Containing Levodropropizine." In September 2023, KUP signed a five-year $52.1 million contract with MCQ, a Thai-based pharmaceutical company, for supply of its mucoactive drug, Levotics CR Tab (levodropropizine).
External links
References
- De Blasio F, Dicpinigaitis PV, Rubin BK, De Danieli G, Lanata L, Zanasi A (January 2012). "An observational study on cough in children: epidemiology, impact on quality of sleep and treatment outcome". Cough. 8 (1): 1. doi:10.1186/1745-9974-8-1. PMC 3274450. PMID 22269875.
- Chan-hyuk, Kim (September 9, 2021). "Korea United Pharm sues 15 drugmakers to protect cough suppressant's patent". Korea Biomedical Review. Retrieved July 29, 2024.
- "Korea United Pharm to supply mucoactive drugs worth $52 million to Thailand". Korea Biomedical Review. September 9, 2023. Retrieved July 29, 2024.
 | This drug article relating to the respiratory system is a stub. You can help Misplaced Pages by expanding it. |